Hua Medicine, Roche To Develop First Chinese-Tailored Diabetes Drug
This article was originally published in PharmAsia News
Roche AG and Hua Medicine Ltd.. begin joint development of diabetes agent ketoacidosis (GKA), aiming to develop the first diabetes treatment tailored for Chinese consumers.
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.